Real-time breast cancer testing during chemotherapy
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial studies real-time molecular testing in people with breast cancer who are receiving chemotherapy before surgery. The goal is to learn how the cancer changes during treatment and whether this helps guide care around surgery and radiation.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman age 18 or older
- You can sign consent to join the study
- You have confirmed invasive breast cancer on biopsy (tissue or cell test)
- Your care team plans chemotherapy before surgery, then radiation after surgery
- You do not have cancer spread to distant organs (no metastatic disease)
- You can complete study visits and follow-up monitoring, and you are able to consent
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial uses a special blood test to track cancer signals (called ctDNA) during and after treatment for early breast cancer. It aims to see whether monitoring these signals can help guide follow-up and treatment decisions.
This trial is testing whether a blood test can track how well chemotherapy is working in people with early-stage triple-negative breast cancer. You would provide blood samples before and during treatment, and the results may help your doctor understand your response better.
This study tests a new blood test to see if it can find tiny bits of tumor DNA after chemotherapy. If you have a larger or higher-risk breast cancer and are getting chemotherapy before surgery, you may join. The test could help doctors know if your cancer is gone or if more treatment is needed.
This trial looks at different drug combinations given before surgery to shrink breast tumors. The goal is to find which treatments work best for different types of breast cancer, such as triple-negative, HER2-positive, or hormone-receptor-positive. If you are a woman scheduled for neoadjuvant therapy (treatment before surgery) and have not had previous cancer treatment, this study may be for you.
This study tests a personalized approach for early-stage breast cancer that is HER2-positive or triple-negative. The goal is to adjust your treatment based on how well the cancer responds to chemotherapy before surgery, so you get the right amount of radiation therapy—no more, no less.
This study looks at how breast cancer cells change during chemotherapy and immunotherapy before surgery. By analyzing tumor samples taken during treatment, doctors hope to find early signs of whether the treatment is working, which could lead to better-personalized care for people with triple negative or high-risk luminal breast cancer.
Hear when a new Breast Cancer Female trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.